Patents by Inventor Phenil Jayantilal Patel

Phenil Jayantilal Patel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GIP/GLP1 CO-AGONIST COMPOUNDS
    Publication number: 20250122259
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: July 2, 2021
    Publication date: April 17, 2025
    Inventors: Jorge ALSINA-FERNANDEZ, Robert Andrew BROWN, Mohamed ElSayed Hamed ELSAYED, Hongchang QU, Huyen Thanh TRAN, Aktham ABURUB, Phenil Jayantilal PATEL
  • GIP/GLP1 co-agonist compounds
    Patent number: 12252524
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: March 18, 2025
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Robert Andrew Brown, Mohamed ElSayed Hamed ElSayed, Hongchang Qu, Huyen Thanh Tran, Aktham Aburub, Phenil Jayantilal Patel
  • GIP/GLP1 CO-AGONIST COMPOUNDS
    Publication number: 20250051415
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: October 18, 2024
    Publication date: February 13, 2025
    Inventors: Jorge ALSINA-FERNANDEZ, Robert Andrew BROWN, Mohamed E.H. ELSAYED, Hongchang QU, Thi Thanh Huyen TRAN, Aktham ABURUB, Phenil Jayantilal PATEL
  • ERODIBLE TABLET
    Publication number: 20240226017
    Abstract: The present invention relates to an erodible tablet comprising a therapeutic peptide which is suitable for oral administration and, in addition, to a non-granulation process for making the erodible tablet.
    Type: Application
    Filed: May 6, 2022
    Publication date: July 11, 2024
    Inventors: Aktham ABURUB, Mridula DOGRA, Mohamed ElSayed Hamed ELSAYED, Siyuan HUANG, Phenil Jayantilal PATEL, Huyen Thanh TRAN
  • GIP/GLP1 CO-AGONIST COMPOUNDS
    Publication number: 20220048967
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: July 2, 2021
    Publication date: February 17, 2022
    Inventors: Milata Mary ABRAHAM, Jorge ALSINA-FERNANDEZ, Robert Andrew BROWN, Over CABRERA, Tamer COSKUN, Robert Chadwick CUMMINS, Mohamed ElSayed Hamed ELSAYED, Hongchang QU, James Lincoln WALLIS, Kyle Wynn SLOOP, Francis Stafford WILLARD, Thi Thanh Huyen TRAN, Aktham ABURUB, Phenil Jayantilal PATEL, Amita DATTA-MANNAN, Xianyin LAI
  • GIP/GLP1 CO-AGONIST COMPOUNDS
    Publication number: 20200024322
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: July 22, 2019
    Publication date: January 23, 2020
    Inventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Robert Andrew Brown, Over Cabrera, Tamer Coskun, Robert Chadwick Cummins, Mohamed ElSayed Hamed Elsayed, Hongchang Qu, James Lincoln Wallis, Kyle Wynn Sloop, Francis Stafford Willard, Thi Thanh Huyen Tran, Aktham Aburub, Phenil Jayantilal Patel, Amita Datta-Mannan, Xianyin Lai
  • Compositions for the Treatment of Inflammation and Pain Using a Combination of a Cox-2 Selective Inhibitor and a Ltb4 Receptor Antagonist
    Publication number: 20080260817
    Abstract: The present invention provides a therapeutic composition comprising a COX-2 selective inhibitor or a prodrug thereof and an LTB4 receptor antagonist. A method is provided for the use of such composition in the treatment, prevention, or inhibition of inflammation, an inflammation-related disorder, pain, or a pain-related disorder.
    Type: Application
    Filed: July 11, 2005
    Publication date: October 23, 2008
    Inventors: Phenil Jayantilal Patel, Po-Chang Chaing